Lyell Immunopharma (LYEL) Projected to Announce Earnings on Tuesday

Lyell Immunopharma (NASDAQ:LYEL) is expected to be posting its Q3 2026 resultson Tuesday, November 10th. Analysts expect the company to announce earnings of ($2.06) per share and revenue of $0.01 million for the quarter. Interested persons may visit the company’s upcoming Q3 2026 earnings report for the latest details on the call scheduled for Friday, November 13, 2026 at 4:00 PM ET.

Lyell Immunopharma (NASDAQ:LYEL) last announced its quarterly earnings results on Thursday, August 6th. The company reported ($1.92) EPS for the quarter, beating analysts’ consensus estimates of ($1.94) by $0.02. The company had revenue of $0.00 million during the quarter, compared to analysts’ expectations of $0.00 million. Lyell Immunopharma had a negative return on equity of 91.62% and a negative net margin of 920,285.25%. On average, analysts expect Lyell Immunopharma to post ($7.16) EPS for the current fiscal year and ($7.21) EPS for the next fiscal year.

Lyell Immunopharma Stock Up 2.1%

NASDAQ LYEL traded up $0.23 during trading on Tuesday, reaching $11.11. 12,095 shares of the stock traded hands, compared to its average volume of 132,635. The firm has a market cap of $272.14 million, a price-to-earnings ratio of -0.87 and a beta of -0.03. The stock’s 50-day moving average price is $10.93 and its 200 day moving average price is $16.83. Lyell Immunopharma has a fifty-two week low of $7.20 and a fifty-two week high of $45.00.

Wall Street Analyst Weigh In

Several brokerages have issued reports on LYEL. Citigroup restated a “market outperform” rating on shares of Lyell Immunopharma in a report on Friday, August 14th. B. Riley Financial began coverage on Lyell Immunopharma in a research report on Wednesday, July 22nd. They issued a “buy” rating and a $44.00 target price on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Lyell Immunopharma in a research note on Thursday, October 15th. HC Wainwright reaffirmed a “buy” rating on shares of Lyell Immunopharma in a research report on Friday, September 11th. Finally, Stifel Nicolaus initiated coverage on shares of Lyell Immunopharma in a research note on Thursday, August 6th. They set a “buy” rating and a $36.00 price target for the company. One equities research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Lyell Immunopharma currently has an average rating of “Moderate Buy” and a consensus price target of $40.86.

Lyell Immunopharma Company Profile

Lyell Immunopharma, Inc is a clinical-stage biotechnology company focused on developing cellular therapies for the treatment of cancer. The company aims to improve the durability and effectiveness of T-cell therapies by addressing challenges such as T-cell exhaustion, limited persistence, and inadequate activity within solid tumors.

Lyell’s research and development programs use technologies designed to reprogram and rejuvenate T cells, including approaches involving genetic engineering, epigenetic modification, and chimeric antigen receptor (CAR) T-cell therapy.